Received Jul 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Administered pediatric Engerix-B dose to a 20 year old patient; Administered pediatric Engerix-B dose to a 20 year old patient; This non-serious case was reported by a physician via sales rep and described the occurrence of adult use of a child product in a 20-year-old female patient who received HBV (Engerix B pediatric) for prophylaxis. On an unknown date, the patient received the 1st dose of Engerix B pediatric (unknown arm). On an unknown date, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: Administered pediatric Engerix-B dose to a 20 year old patient) and underdose (Verbatim: Administered pediatric Engerix-B dose to a 20 year old patient). The outcome of the adult use of a child product and underdose were not applicable. Additional Information: GSK Receipt Date: 10-JUL-2025 The physician reported that they administered pediatric Engerix-B dose to a 20-year-old patient, which led to adult use of a child product and underdose